Knight Therapeutics Inc (CVE:GUD) had its price objective decreased by National Bank Financial from C$10.75 to C$10.50 in a research note published on Monday morning. National Bank Financial currently has an outperform rating on the specialty pharmaceutical company’s stock.

Knight Therapeutics (GUD) remained flat at $C$6.14 during midday trading on Monday. Knight Therapeutics has a one year low of C$3.51 and a one year high of C$7.24.

COPYRIGHT VIOLATION WARNING: “Knight Therapeutics Inc (GUD) Given New C$10.50 Price Target at National Bank Financial” was originally reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this piece on another website, it was stolen and republished in violation of US & international trademark & copyright laws. The correct version of this piece can be accessed at https://www.thecerbatgem.com/2017/11/13/knight-therapeutics-inc-gud-given-new-c10-50-price-target-at-national-bank-financial.html.

Knight Therapeutics Company Profile

Knight Therapeutics Inc, a specialty pharmaceutical company, engages in developing, acquiring, in-licensing, out-licensing, marketing, and distributing pharmaceutical products, consumer health products, and medical devices in Canada and internationally. The company’s commercialized products include Impavido, an alkyllysophospholipid analogue drug for the treatment of visceral and cutaneous Leishmaniasis; Movantik for the treatment of opioid induced constipation; AzaSite to treat bacterial conjunctivitis; Neuragen to treat pain associated with diabetic and peripheral neuropathy; Flat Tummy Tea, a herbal detox tea; and FOCUSfactor, a dietary supplement.

Receive News & Stock Ratings for Knight Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Knight Therapeutics Inc and related stocks with our FREE daily email newsletter.